Search

Search Constraints

You searched for: Author/Creator Hau, Peter

Search Results

1. 136 Complete Resection of Contrast-Enhancing Tumor Volume is Associated With Improved Survival in Recurrent Glioblastoma Results From the DIRECTOR Trial. (August 2015)

2. A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression. Issue 2 (17th September 2022)

3. ACTR-49. PriCoTTF: A PHASE I/II TRIAL OF TUMOR TREATING FIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA. (5th November 2018)

4. ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL. (11th November 2019)

5. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Issue 6 (June 2021)

6. AIDS-Related Central Nervous System Toxoplasmosis With Increased 18F-Fluoroethyl-L-Tyrosine Amino Acid PET Uptake Due to LAT1/2 Expression of Inflammatory Cells. (December 2017)

9. BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA. (12th November 2021)

10. BIOM-24. PROTEIN SURFACE SIGNATURE ON SERUM EXTRACELLULAR VESICLES FOR NON-INVASIVE DETECTION OF TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS. (12th November 2021)